QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • ADVENTRX Pharmaceuticals (ANX) Meets with FDA Regarding Plans for ANX-188 Treatment 0 comments
    Dec 1, 2011 1:50 PM | about stocks: MSTX

    Today, ADVENTRX Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing proprietary product candidates, announced that it met with the U.S. Food and Drug Administration (FDA) to review development plans for ANX-188 (purified poloxamer 188). ANX-188 is the company’s first-in-class treatment for sickle cell patients who experience vaso-occlusive crisis.

    At the meeting, ADVENTRX and the FDA discussed topics related to the overall development of ANX-188, in addition to discussions regarding the design of a phase 3 study for the treatment of sickle cell patients experiencing vaso-occlusive crisis.

    Brian M. Culley, Chief Executive Officer of ADVENTRX, remarked, “As part of our commitment to a strong relationship with FDA, we have met with the Agency four times in recent months to discuss development plans for our product candidates. In particular, with a complex condition such as sickle cell crisis, it is crucial to have clarity around all aspects of our development plans for ANX-188. We appreciate FDA’s continued involvement and look forward to further dialogue with the Agency, which will allow us to reach agreement on a path to approval for ANX-188 for the benefit of sickle cell patients.”

    While ADVENTRX and the FDA reached an understanding regarding certain matters, the entities will communicate over the next several weeks and months to finalize development plans for ANX-188. During that time, the company will continue to make progress on the manufacture of clinical trial material for a phase 3 study to occur sometime in 2012.

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net


    Stocks: MSTX
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.